ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a ...
And check out Exciting 2026 virtual and in-person programs with Hospital for Special Surgery! on the East Meadow Patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback